Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 1

2(40.0%)

Phase 2

1(20.0%)

5Total

Phase 3(2)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04693520Phase 2Completed

Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease

Role: lead

NCT04770220Phase 3Completed

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

Role: lead

NCT06304883Phase 3Active Not Recruiting

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Role: lead

NCT04585347Phase 1Completed

Single Dose Study of ALZ-801 Prototype Tablets

Role: lead

NCT04157712Phase 1Completed

Multiple Ascending Dose Study of ALZ-801

Role: lead

All 5 trials loaded